Zoetis Q3: Strong Osteoarthritis Pain Franchise

seekingalpha11-11

I reiterate a 'Buy' rating for Zoetis with a one-year target price of $210 per share, driven by strong product performance and strategic divestitures.The Company's osteoarthritis drugs, LIBRELA and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482407072?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1629582255/image_1629582255.jpg","is_english":true,"pubTime":"2024-11-11 12:18","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2482407072","market":"sg","top_or_hot":-1,"title":"Zoetis Q3: Strong Osteoarthritis Pain Franchise","media":"seekingalpha","content":"<div>\n<p>I reiterate a 'Buy' rating for Zoetis with a one-year target price of $210 per share, driven by strong product performance and strategic divestitures.The Company's osteoarthritis drugs, LIBRELA and ...</p>\n\n<a href=\"https://seekingalpha.com/article/4735954-zoetis-q3-strong-osteoarthritis-pain-franchise\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zoetis Q3: Strong Osteoarthritis Pain Franchise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZoetis Q3: Strong Osteoarthritis Pain Franchise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-11 12:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4735954-zoetis-q3-strong-osteoarthritis-pain-franchise><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I reiterate a 'Buy' rating for Zoetis with a one-year target price of $210 per share, driven by strong product performance and strategic divestitures.The Company's osteoarthritis drugs, LIBRELA and ...</p>\n\n<a href=\"https://seekingalpha.com/article/4735954-zoetis-q3-strong-osteoarthritis-pain-franchise\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0471298777.SGD","symbol_name":"Blackrock Nutrition A2 SGD-H","start_time":0,"source_url":"https://seekingalpha.com/article/4735954-zoetis-q3-strong-osteoarthritis-pain-franchise","article_id":"2482407072","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1629582255/image_1629582255.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482407072","pubTimestamp":1731298718,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"I reiterate a 'Buy' rating for Zoetis with a one-year target price of $210 per share, driven by strong product performance and strategic divestitures.The Company's osteoarthritis drugs, LIBRELA and SOLENSIA, delivered 97% operational revenue growth, with LIBRELA poised to become a $1 billion franchise.Zoetis projects 10–11% operational revenue growth and 13.5–14.5% adjusted net income growth for FY24, despite minor headwinds from China.ZTS's strategic divestiture of non-core assets and strong market position in companion animal drugs support a robust growth outlook.Tom Werner  I upgraded Zoetis  to a 'Buy' rating in August 2024, highlighting the company's direct-to-customer strategy and investment in new products. Zoetis delivered a strong growth in Q3 FY24, with 14% year-over-year growth in both revenue and adjusted net income. Notably, their companion animal","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","BK4007":"制药","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","LU2308191902.HKD":"BNP PARIBAS ECOSYSTEM RESTORATION \"CLASSIC\" (HKD) ACC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","ZTS":"Zoetis Inc.","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","BK4588":"碎股","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU0385154629.USD":"贝莱德营养科学基金A2","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0079474960.USD":"联博美国增长基金A","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC"},"translate_title":"硕腾Q3：强骨关节炎疼痛加盟","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZTS":0.9},"content_text":"I reiterate a 'Buy' rating for Zoetis with a one-year target price of $210 per share, driven by strong product performance and strategic divestitures.The Company's osteoarthritis drugs, LIBRELA and SOLENSIA, delivered 97% operational revenue growth, with LIBRELA poised to become a $1 billion franchise.Zoetis projects 10–11% operational revenue growth and 13.5–14.5% adjusted net income growth for FY24, despite minor headwinds from China.ZTS's strategic divestiture of non-core assets and strong market position in companion animal drugs support a robust growth outlook.Tom Werner  I upgraded Zoetis (NYSE:ZTS) to a 'Buy' rating in August 2024, highlighting the company's direct-to-customer strategy and investment in new products. Zoetis delivered a strong growth in Q3 FY24, with 14% year-over-year growth in both revenue and adjusted net income. Notably, their companion animal","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"analysis","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482407072"}